Compare ANDE & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANDE | DNTH |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2005 | 2018 |
| Metric | ANDE | DNTH |
|---|---|---|
| Price | $63.95 | $65.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $75.00 | ★ $82.33 |
| AVG Volume (30 Days) | 262.9K | ★ 647.1K |
| Earning Date | 05-20-2026 | 04-06-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | 12.93 | ★ 69.82 |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $11,008,928,000.00 | $6,235,000.00 |
| Revenue This Year | $13.28 | N/A |
| Revenue Next Year | $5.76 | N/A |
| P/E Ratio | $77.63 | ★ N/A |
| Revenue Growth | N/A | ★ 120.63 |
| 52 Week Low | $31.03 | $13.37 |
| 52 Week High | $70.06 | $64.67 |
| Indicator | ANDE | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 76.23 |
| Support Level | $62.90 | $33.94 |
| Resistance Level | $70.06 | N/A |
| Average True Range (ATR) | 2.26 | 3.69 |
| MACD | -0.59 | 1.23 |
| Stochastic Oscillator | 28.93 | 98.34 |
Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.